康柏西普玻璃体腔注射治疗糖尿病性有临床意义黄斑水肿的疗效观察

Clinical effects of diabetic macular edema treated with intravitreal Conbercept injection

目的分析康柏西普玻璃体腔注射治疗糖尿病性有临床意义黄斑水肿(CSME)的临床效果。方法回顾性分析2018年1月—2019年12月间运城立明眼科医院收治的糖尿病性CSME患者60例,按治疗方案分为康柏西普组(观察组)及雷珠单抗组(对照组),治疗后随访6个月,比较治疗前后患者的最佳矫正视力(BCVA),黄斑中心凹厚度(CMT)改变情况,重复用药次数。结果分别接受康柏西普组和雷珠单抗注射1,3,6个月后,2组患者的BCVA均较治疗前发生明显改善,且接受康柏西普治疗的观察组患者在治疗1个月、3个月和6个月后的BCVA高于对照组(P<0.05);2组治疗后1个月、3个月、6个月的CMT均优于治疗前,观察组患者的CMT在治疗后3,6个月时显著低于对照组(P<0.05);观察组治疗后6个月随访期内重复用药次数少于对照组(P<0.05)。结论康柏西普玻璃体腔注射治疗糖尿病性CSME临床效果显著,值得推广。

Objective To analyze the clinical effect of intravitreal injection of Conbercept in the treatment of diabetic macular edema(CSME).Methods A retrospective analysis of 60 diabetic CSME patients admitted to our hospital from January 2018 to December 2019 was divided into the Conbercept group(observation group)and the Ranibizumab group(control group)according to the treatment plan.Followed up for 6 months after treatment,compared the patients'best corrected visual acuity(BCVA),macular thickness changes before and after treatment,and the number of repeated medications.Results After 1 month,3 months,and 6 months of treatment,the BCVA of the two groups of patients was better than before treatment,and the BCVA of the observation group after 3 and 6 months of treatment was better than the control group(P<0.05);1 month,3 months,and 6 months after treatment were better than before treatment.The thickness of the fovea in the observation group was significantly lower than that in the control group at 3 and 6 months after treatment(P<0.05);The number of repeated medications in study group was less than that in the control group during the monthly follow-up period(P<0.05).Conclusion The clinical effects of intravitrealConberceptinjection in the treatment of diabetic CSME is remarkable,and it is worthy of promotion.